2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.
Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma (MCL).
Several unique data points were noted from the analysis, Riedell explains. For example, the data showed that when employing a multivariate analysis, the effect of relapse on overall survival (OS) varied with time, Riedell says. Additionally, the effect of relapse was the greatest at early time points after patients had undergone an autologous hematopoietic cell transplant (AHCT), Riedell explains. Moreover, patients who relapsed by the 6-, 12-, or 18-month landmark time points following AHCT had the worst outcomes overall, Riedell says.
Moreover, patients aged 60 years or older had worse OS at the various landmark time points compared with younger patients, which is consistent with other previously published data, Riedell concludes.
Related Content: